Skip to main content

Advertisement

Table 3 Associations of oxidative stress-related DNA methylation at the selected CpG sites with cancer incidences and mortality outcomes

From: The associations of DNA methylation alterations in oxidative stress-related genes with cancer incidence and mortality outcomes: a population-based cohort study

Outcomes cg25365794 cg08862778
HR (95% CI)* HR (95% CI)*
Overall incident cancer#
 Tertile 1 Ref. Ref.
 Tertile 2 0.77 (0.59, 1.01) 0.93 (0.71, 1.21)
 Tertile 3 0.90 (0.68, 1.18) 0.84 (0.62, 1.12)
 Increase per 1 SD 0.98 (0.87, 1.10) 0.99 (0.87, 1.12)
Incident lung cancer
 Tertile 1 Ref. Ref.
 Tertile 2 0.73 (0.46, 1.16) 0.90 (0.57, 1.41)
 Tertile 3 0.78 (0.48, 1.27) 0.67 (0.40, 1.11)
 Increase per 1 SD 0.81 (0.66, 0.99) 0.94 (0.77, 1.15)
Incident colorectal cancer
 Tertile 1 Ref. Ref.
 Tertile 2 0.72 (0.43, 1.19) 1.07 (0.65, 1.76)
 Tertile 3 0.83 (0.50, 1.40) 1.46 (0.88, 2.44)
 Increase per 1 SD 0.98 (0.79, 1.21) 1.16 (0.96, 1.41)
Incident breast cancer (in female participants)
 Tertile 1 Ref. Ref.
 Tertile 2 0.91 (0.55, 1.51) 0.67 (0.40, 1.11)
 Tertile 3 0.91 (0.50, 1.65) 0.57 (0.33, 0.97)
 Increase per 1 SD 0.90 (0.70, 1.16) 0.84 (0.63, 1.11)
Incident prostate cancer#(in male participants)
 Tertile 1 Ref. Ref.
 Tertile 2 0.47 (0.24, 0.92) 0.97 (0.49, 1.92)
 Tertile 3 0.68 (0.37, 1.24) 1.11 (0.51, 2.42)
 Increase per 1 SD 0.78 (0.60, 1.03) 1.15 (0.82, 1.62)
All-cause mortality
 Tertile 1 Ref. Ref.
 Tertile 2 0.90 (0.74, 1.11) 0.99 (0.80, 1.22)
 Tertile 3 1.14 (0.93, 1.41) 1.17 (0.93, 1.47)
 Increase per 1 SD 1.03 (0.94, 1.12) 1.08 (0.98, 1.18)
Cancer mortality
 Tertile 1 Ref. Ref.
 Tertile 2 0.91 (0.69, 1.20) 0.87 (0.66, 1.16)
 Tertile 3 0.87 (0.65, 1.16) 0.97 (0.71, 1.31)
 Increase per 1 SD 0.92 (0.81, 1.05) 1.06 (0.94, 1.20)
CVD mortality
 Tertile 1 Ref. Ref.
 Tertile 2 0.87 (0.65, 1.16) 1.04 (0.77, 1.40)
 Tertile 3 1.23 (0.92, 1.66) 1.28 (0.93, 1.75)
 Increase per 1 SD 1.04 (0.92, 1.17) 1.08 (0.95, 1.22)
  1. Numbers printed in italics: statistically significantly different from 1 (P < 0.05)
  2. Abbreviations: CI confidence interval, CVD cardiovascular disease, HR hazard ratio, SD standard deviation
  3. *The Cox regression model was adjusted for age, sex, batch, and leukocyte distribution
  4. #Meta-analyzed results from subset I (cohort design, n = 1000), sub-cohort of subset II (cohort design, n = 548), and sub-cohort of subset III (cohort design, n = 741)
  5. Meta-analyzed results from subset I (cohort design, n = 1000), sub-cohort of subset II (cohort design, n = 548), subset III (case-cohort design, n = 741; sub-cohort, n = 80 lung cancer cases, n = 37 colorectal cancer cases), and subset IV (nested case-control design, n = 65 lung cancer cases, n = 100 colorectal cancer cases, n = 176 controls)
  6. Meta-analyzed results from subset I (cohort design, n = 1000), sub-cohort of subset II (cohort design, n = 548), and subset III (case-cohort design, n = 741; sub-cohort, n = 128 breast cancer cases)
  7. Meta-analyzed results from subset I (cohort design, n = 1000), subset II (case-cohort design, n = 548; sub-cohort, n = 316 all-cause mortality, n = 128 cancer mortality, n = 104 CVD mortality), and subset III (case-cohort design, n = 741; sub-cohort, n = 538 all-cause mortality, n = 209 cancer mortality, n = 181 CVD mortality)